Otrivine Sinusitis Relief (Xylometazoline Hydrochloride)

Xylometazoline hydrochloride acts as an alpha‑adrenergic agonist. By stimulating alpha‑1 receptors on the blood vessels of the nasal mucosa, it causes vasoconstriction, which decreases mucosal edema and opens the nasal airways, providing rapid decongestion.

The specific dosing regimen for Otrivine Sinusitis Relief is determined by the prescribing healthcare professional based on the patient’s age, condition, and response to therapy. Patients should follow the prescriber’s instructions and not exceed the recommended number of sprays per day.

Pregnant or breastfeeding individuals should consult their healthcare provider before using Otrivine Sinusitis Relief. The prescriber will weigh the potential benefits against any possible risks to the mother and infant before recommending use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Otrivine Sinusitis Relief contains xylometazoline, which provides rapid vasoconstriction similar to other topical decongestants such as oxymetazoline. Compared with systemic decongestants, it offers localized action with fewer systemic effects, but it shares the same risk of rebound congestion if used beyond the recommended duration.

Store the nasal spray at room temperature, ideally below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use to maintain product stability.

The product is administered as a nasal spray. The user gently inserts the tip into one nostril, tilts the head slightly forward, and sprays the prescribed number of sprays while breathing in gently. The process is then repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include nasal septum perforation, severe hypertension from systemic absorption, and rebound congestion after prolonged use. Patients should seek medical attention if they notice persistent nosebleeds, severe pain, or worsening congestion after stopping the spray.

Individuals with known hypersensitivity to xylometazoline or any component of the formulation should avoid the product. It is also contraindicated in patients with severe hypertension, coronary artery disease, or those who have undergone recent nasal surgery unless advised otherwise by a healthcare professional.